Evaluation of nanoparticle uptake in co-culture cancer models

PLoS One. 2013 Jul 26;8(7):e70072. doi: 10.1371/journal.pone.0070072. Print 2013.

Abstract

Co-culture models are currently bridging the gap between classical cultures and in vivo animal models. Exploring this novel approach unlocks the possibility to mimic the tumor microenvironment in vitro, through the establishment of cancer-stroma synergistic interactions. Notably, these organotypic models offer a perfect platform for the development and pre-clinical evaluation of candidate nanocarriers loaded with anti-tumoral drugs in a high throughput screening mode, with lower costs and absence of ethical issues. However, this evaluation was until now limited to co-culture systems established with precise cell ratios, not addressing the natural cell heterogeneity commonly found in different tumors. Therefore, herein the multifunctional nanocarriers efficiency was characterized in various fibroblast-MCF-7 co-culture systems containing different cell ratios, in order to unravel key design parameters that influence nanocarrier performance and the therapeutic outcome. The successful establishment of the co-culture models was confirmed by the tissue-like distribution of the different cells in culture. Nanoparticles incubation in the various co-culture systems reveals that these nanocarriers possess targeting specificity for cancer cells, indicating their suitability for being used in this illness therapy. Additionally, by using different co-culture ratios, different nanoparticle uptake profiles were obtained. These findings are of crucial importance for the future design and optimization of new drug delivery systems, since their real targeting capacity must be addressed in heterogenous cell populations, such as those found in tumors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Cell Line, Tumor
  • Coculture Techniques
  • Drug Carriers / analysis
  • Drug Carriers / metabolism*
  • Drug Delivery Systems
  • Fibroblasts / cytology
  • Humans
  • Nanoparticles / analysis
  • Nanoparticles / metabolism*
  • Neoplasms / drug therapy
  • Neoplasms / metabolism

Substances

  • Antineoplastic Agents
  • Drug Carriers

Grants and funding

This work was supported by the Portuguese Foundation for Science and Technology (FCT), SFRH/BD/80402/2011,PTDC/EME-TME/103375/2008, PTDC/EBB-BIO/114320/2009 and PEst-OE/EGE/UI4056/2011. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.